SCHEMBL3340741

SCHEMBL3340741

COC(=O)c1cccc(C(O)c2cccc(C)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR17 Q13304 1/20 0.50
KDM5A P29375 1/20 0.50
LOXL2 Q9Y4K0 1/20 0.46
ADRB2 P07550 2/20 0.46
ADRB1 P08588 2/20 0.46
ADRB3 P13945 2/20 0.46
TSHR P16473 1/20 0.46
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
TCF4 P15884 1/20 0.45
CTNNB1 P35222 1/20 0.45
TDP1 Q9NUW8 1/20 0.44
ALDH1A1 P00352 2/20 0.44
MAPT P10636 1/20 0.44
HPGD P15428 1/20 0.44
POLB P06746 1/20 0.44
RAB9A P51151 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
SLC7A5 Q01650 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3636710 0.89 TDP1 (0.51) GPR17LOXL2TSHRCYP4F2CYP4A11
SCHEMBL9149153 0.89 TDP1 (0.51) GPR17KDM5ALOXL2ADRB2ADRB1
SCHEMBL3340488 0.87 TSHR (0.58) LOXL2TSHRCYP4F2CYP4A11ALDH1A1
SCHEMBL1568650 0.83 ADRB2 (0.54) LOXL2ADRB2ADRB1ADRB3TSHR
SCHEMBL29534771 0.83 GPR17 (0.65) GPR17LOXL2TSHRCYP4F2CYP4A11
SCHEMBL40429 0.83 GPR17 (0.65) GPR17LOXL2TSHRCYP4F2CYP4A11
SCHEMBL28289702 0.83 GPR17 (0.65) GPR17LOXL2TSHRCYP4F2CYP4A11
SCHEMBL2458334 0.82 KMT2A (0.46) LOXL2TSHRCYP4F2CYP4A11ALDH1A1
SCHEMBL4407209 0.82 TSHR (0.53) LOXL2TSHRCYP4F2CYP4A11ALDH1A1
SCHEMBL2650423 0.82 TSHR (0.53) LOXL2TSHRCYP4F2CYP4A11ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160424-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-06-24 US disclosed
US-20100160424-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-06-24 US disclosed
US-20100160424-A1 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. 2010-06-24 US disclosed
EP-2170815-A2 RENIN INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2010-04-07 EP disclosed
WO-2008156817-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2008-12-24 WO disclosed
WO-2008156817-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160424-A1 RENIN INHIBITORS ACE, REN, DNPEP GPR17 2943/4885KDM5A 4419/4885LOXL2 2685/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.